Jun 26, 1999 | NEWS
The following article by Laura Spinney appears in BioMednews Reports (6- 25-99,#57) Glycogen storage disease type II causes enlargement of certain muscles, particularly the heart and tongue, due to their inability to break down glycogen. A team of American scientists...
Jan 18, 1999 | NEWS
Orphan Drug Designation A drug becomes an “orphan” when it receives orphan designation from the Office of Orphan Products Development, FDA. An orphan drug is a drug intended to treat diseases or conditions affecting fewer than 200,000 people per year in the United...
Jan 4, 1999 | NEWS
Following is background information and a Q & A released by the Pharming/Genzyme LLC on important issues concerning clinical trials for enzyme replacement therapy now underway in the Netherlands on acid maltase deficiency, Pompe’s disease. Background—Pompe Disease...
Oct 15, 1998 | NEWS
Leiden, the Netherlands/Cambridge, Mass., October 14, 1998—Pharming Group N.V. (Easdaq: PHAR), the Netherlands biopharmaceutical company, and the American biotechnology company Genzyme General (Nasdaq: GENZ), has created a joint venture to develop and commercialize...
Jul 22, 1998 | NEWS
Human Gene Therapy 9:1609-1616 (July 20, 1998) Mary Ann Liebert, Inc. Adenovirus-Mediated Transfer of Human Acid Maltase Gene Reduces Glycogen Accumulation in Skeletal Muscle of Japanese Quail with Acid Maltase Deficiency S. Tsujino 1), N. Kinoshita 1), T. Tashiro 1),...
